ArticleLupus science & medicine2025
Epidemiology of patients with moderate-to-severe SLE in Sweden.
Article in Lupus science & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSLE affects multiple organs and is associated with increased mortality and organ damage. While treatment recommendations for non-renal SLE stratify by disease activity, no standard approach to measuring severity exists. This study aimed to estimate the prevalence and incidence of SLE in Sweden, quantify patients with moderate-to-severe disease using register-based algorithms and examine associations between disease severity and survival.
methodsWe identified adult SLE patients in the Swedish National Patient Register with at least two SLE-coded visits between July 2005 and December 2019. Annual incidence and point prevalence were calculated. SLE patients were matched 5:1 with non-SLE comparators. SLE disease severity was classified annually postdiagnosis using an adapted algorithm based on prescriptions and comorbidities. Survival between SLE patients by each severity level in the year following diagnosis was compared with matched comparators using Cox regression models.
resultsIn total, 10 186 SLE patients were identified, including 5076 incident cases. The average incidence of adult SLE in Sweden between 2015 and 2019 was 4.1 cases per 100 000, with a 2019 prevalence of 93.8 per 100 000. In the first year postdiagnosis, 61% of SLE patients had moderate-to-severe disease, stabilising at approximately 45% after 3-4 years among patients still in follow-up. Across all severity levels, SLE patients had poorer survival than comparators. High severity in the year following diagnosis was independently associated with increased mortality risk compared with mild disease, regardless of age, sex or prescribed treatments.
conclusionsUsing national register data, the estimated prevalence of SLE in Sweden is higher than published figures from previous years. This is the first Swedish register-based study characterising SLE severity and its survival impact. Mortality risk is particularly increased in patients with moderate or severe SLE at diagnosis, underscoring the need for targeted strategies to improve outcomes for this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.